Sanofi wins FDA OK for Priftin in 'latent' TB
This article was originally published in Scrip
Executive Summary
The FDA has approved Sanofi's Priftin (rifapentine) in combination with isoniazid indication for the treatment of latent tuberculosis infection (LTBI) in patients two years of age and older at high risk of progression to tuberculosis (TB).